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MMP-9 Supplied by Bone Marrow–Derived Cells
Contributes to Skin Carcinogenesis
esis, and tumor progression (Coussens and Werb, 1996;
Wilson et al., 1997; Cockett et al., 1998; Vu et al., 1998;
Sternlicht et al., 1999; Stetler-Stevenson, 1999). Among
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a significant factor in cancer despite studies with MMP-3 Department of Pathology
4 Department of Biochemistry and Biophysics 9-expressing tumor cells correlating its activity with ma-
lignant growth potential. MMP-9 can be expressed by5 Department of Anatomy
6 UCSF Comprehensive Cancer Center epithelial and nonepithelial cell types, including fibro-
blasts, endothelial cells, and cells of hematopoietic ori-University of California, San Francisco
513 Parnassus Avenue gin (reviewed in Vu and Werb, 1998). Interestingly, recent
studies have suggested a role for inflammatory cells,San Francisco, California 94143
which are a source of MMP-9, in cancer phenotypes
(Dvorak, 1986; Cordon-Cardo and Prives, 1999; Cous-
sens et al., 1999; Fosslien, 2000).
We have studied a transgenic mouse model of epithe-Summary
lial carcinogenesis that involves expression of the hu-
man papillomavirus type 16 (HPV16) early region genesThe matrix metalloproteinase MMP-9/gelatinase B is
in basal keratinocytes (Arbeit et al., 1994); the K14-upregulated in angiogenic dysplasias and invasive
HPV16 mice reproducibly show multistage developmentcancers of the epidermis in a mouse model of multi-
of invasive squamous cell carcinoma (SCC) of the epi-stage tumorigenesis elicited by HPV16 oncogenes.
dermis (Coussens et al., 1996). Animals are born pheno-Transgenic mice lacking MMP-9 show reduced kera-
typically normal; by one month of age, with 100% pene-tinocyte hyperproliferation at all neoplastic stages and
trance, epidermal hyperplasias appear, and advancea decreased incidence of invasive tumors. Yet those
focally into angiogenic dysplasias between 3 and 6carcinomas that do arise in the absence of MMP-9
months. Angiogenic dysplasias are characterized by in-exhibit a greater loss of keratinocyte differentiation,
tense mast cell infiltration of the reactive stroma, andindicative of a more aggressive and higher grade tu-
increased density and altered architecture of capillariesmor. Notably, MMP-9 is predominantly expressed in
(Smith-McCune et al., 1997; Coussens et al., 1999). Byneutrophils, macrophages, and mast cells, rather than
one year of age, 50% of transgenic mice develop inva-in oncogene-positive neoplastic cells. Chimeric mice
sive SCCs, of which z20% metastasize to regionalexpressing MMP-9 only in cells of hematopoietic ori-
lymph nodes (Coussens et al., 1996). SCCs most fre-gin, produced by bone marrow transplantation, recon-
quently develop on ear (25%) and truncal (72%) skin,stitute the MMP-9-dependent contributions to squa-
and, less frequently, on the head (2%) and appendagesmous carcinogenesis. Thus, inflammatory cells can be
(1%); the tumors emerge out of dysplastic skin lesions.coconspirators in carcinogenesis.
In this report, we have evaluated the role of MMP-9
during carcinogenesis in K14-HPV16 transgenic mice.
Introduction
The data indicate that MMP-9 expressed by inflamma-
tory cells is functionally involved in distinct processes
Epithelial tumors are composed of both transformed,
of epithelial carcinogenesis: regulation of oncogene-
genetically altered epithelial cells and a variety of “nor-
induced keratinocyte hyperproliferation, progression to
mal” cells, including endothelial cells forming the tumor
invasive cancer, and end-stage malignant grade.
vasculature, fibroblasts, and inflammatory cells (lympho-
cytes, macrophages, mast cells, neutrophils). As tumors
Resultsevolve in a stepwise fashion, malignant progression of
neoplastic cells is driven by intrinsic events, such as
MMP-9 Is Upregulated Early during Neoplasticactivation of oncogenes and/or loss of tumor suppres-
Progression in K14-HPV16 Transgenic Micesor genes; increasingly, evidence is accumulating that
Extensive extracellular matrix (ECM) remodeling, char-extrinsic factors present in the local microenvironment
acterized by collagen fibril degradation and epithelialare also influential in tumorigenesis.
basement membrane thinning, occurs early in neoplas-Proteinases play pivotal roles in altering local micro-
tic progression prior to frank tumor cell invasion inenvironments during embryonic development and growth
HPV16 transgenic mice (Coussens et al., 1996). To char-as well as in tissue remodeling (physiologic and patho-
acterize proteolytic activities associated with this ECMlogic) processes. In particular, matrix metalloprotei-
remodeling, we used gelatin substrate zymography tonases (MMPs) such as gelatinase B/MMP-9, gelatinase
reveal temporal changes in gelatinolytic activities in ly-A/MMP-2, stromelysin-1/MMP-3, and matrilysin/MMP-7
sates of staged neoplastic tissue (Figure 1). The proen-have emerged as regulators of development, angiogen-
zyme form of MMP-9 was not detectable in normal skin,
but was incrementally upregulated in hyperplastic, dys-
plastic, and tumor tissue. Active MMP-9 was detected7 To whom correspondence should be addressed (e-mail: coussens@
cc.ucsf.edu). at low levels in some hyperplasias and was abundant
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ogenesis. By 7 months of age, 90% had progressed to
dysplasia; however, the lesions that did develop were
more focal and limited in the extent of skin involvement
compared to age-matched controls. The HPV16/MMP-9
2/2 mice also exhibited a reduced incidence of malig-
nant conversion. Only 27% of HPV16/MMP-9 2/2 mice
(p , 0.0001; Fisher’s Exact Test) developed tumors, in
contrast to the z50% incidence in MMP-9-proficient/
HPV16 mice (Figure 2A). The average number of SCCs
Figure 1. MMP-2 and MMP-9 Are Activated during Epithelial Carci- per mouse (1.06% 6 0.12) and their anatomic locations
nogenesis in HPV16 Transgenic Mice
(ear, 23%–29%; trunk, 51%–54%; head, 5%–16%; ap-
Gelatin-substrate zymography of skin biopsies from ear skin of neg-
pendages, 10%–12%) in all three cohorts (1/1, 1/2,ative litter mates (norm) and K14-HPV16 transgenic mice with hyper-
2/2) did not change significantly.plastic (hyp), dysplastic (dys) and Grade II SCCs. Arrows indicate
location of enzymatic activity corresponding to pro- and active
forms of MMP-9 and MMP-2. Molecular weight markers (kDa) are Tumors Arising in HPV16/MMP-9 2/2 Mice Are
shown at left. More Malignant
Tumors that arise in MMP-9-proficient/HPV16 mice
represent a spectrum of carcinoma grades based on
in 100% of dysplastic and tumor tissue lysates (Figure characteristic epithelial differentiation markers, ranging
1). Gelatinase A/MMP-2 (latent and active) was also not predominantly from well-differentiated (Grade I) carcino-
detected in normal skin, but the proenzyme form was mas to infrequent poorly differentiated (Grade IIII) carci-
present in hyperplastic, dysplastic, and tumor lysates. nomas and rare Grade IV cancers (Figures 2B and 2C).
Notably, active MMP-2 was detected only in lysates of Because the SCCs that arose in MMP-9-deficient/
tumors (Figure 1). A serine proteinase, mast cell prote- HPV16 did so with lower frequency and extended la-
ase-4, was also detected by gelatin zymography in dys- tency, our expectation was that they would tend toward
plastic and some tumor tissue lysates (Coussens et al., a more terminally differentiated cancer phenotype. To
1999). assess this, we graded tumors based on the expression
of keratin intermediate filament isoforms (Broders, 1932;
Lane and Alexander, 1990; Coussens et al., 1996). TheAbsence of MMP-9 Decreases the Incidence
most well-differentiated tumors expressed keratins 10of Carcinomas
and 14, but not the simple epithelial keratin K8, andTo assess the functional significance of elevated MMP-9
were classified as Grade I SCCs (Figure 2B). Tumorsactivity during neoplastic progression in HPV16 trans-
expressing K10, K14, and K8 were classified as Gradegenic mice, we adopted a genetic approach utilizing
II SCCs, whereas poorly differentiated tumors no longermice carrying a homozygous disruption of the MMP-9
expressing K10, while retaining expression of K14 andgene (Vu et al., 1998). HPV16/MMP-9 1/2 mice, bred
K8, were classified as Grade III SCCs (Figure 2B). Wefour generations into FVB/n (n 5 76), were phenotypi-
defined carcinomas with a spindle cell appearance ascally and histopathologically indistinguishable from
Grade IV SCCs, consistent with an epithelial-to-mesen-control HPV16 transgenic mice (n 5 133). With 100%
chymal transition that suppressed expression of keratinpenetrance, HPV16/MMP-9 1/2 mice develop hyper-
intermediate filaments and increased expression of vi-plastic skin that is visually discernible at weaning, fol-
mentin, a mesenchymal cell marker (Sternlicht et al.,lowed by development of angiogenic dysplasias by 4
1999; Figure 2B).months of age (data not shown). HPV16/MMP-9 1/2
Remarkably, the distribution of tumors in HPV16/mice exhibited a similar latency and incidence of SCC
MMP-9 2/2 mice was biased toward carcinomas thatdevelopment (46%) by 12 months of age as HPV16/
expressed less differentiated or embryonic phenotypesMMP-9 1/1 mice (50%), with the earliest cancers also
representative of higher malignant grades, compared toarising at z3 months (Figure 2A).
tumors from HPV16/MMP-9 1/2 and 1/1 controls.In contrast, HPV16/MMP-9 2/2 mice (n 5 137)
Well-differentiated Grade I cancers decreased in theshowed a marked delay in development of the charac-
absence of MMP-9 from 57.5% (MMP-9-proficient/teristic hyperplastic and dysplastic phenotypes. At
HPV16 mice) to 21.4% in MMP-9 null mice. In contrast,weaning, the HPV16/MMP-9 2/2 mice did not show
the percentage of Grade II, III, and IV cancers all in-hyperplasias and were not phenotypically distinguish-
creased in the absence of MMP-9 (Grade II, 35%able from their MMP-9 2/2 non-HPV16 littermates (data
to 42.8%; Grade III, 7.5% to 28.5%; Grade IV, 0% tonot shown). However, by 2 months of age, 100% of
7.1%; p , 0.0001, Wilcoxon Score for Variable Grade;HPV16/MMP-9 2/2 mice showed a mildly hyperplastic
Figure 2C).epidermis, characterized by a 2-fold increase in all
keratinocyte layers with retention of complete terminal
differentiation capacity, minimal stromal remodeling, Keratinocyte Hyperproliferation Is Restricted
in MMP-9-Deficient/HPV16 Miceand inflammatory cell infiltration, more typical of 3- to
4-week-old HPV16 controls (data not shown). By 4 A tumor’s aggressiveness is commonly graded in terms
of the extent to which it has lost normal differentiatedmonths of age, only z20% of HPV16/MMP-9 2/2 mani-
fested dysplasias characterized by loss of keratinocyte characteristics, and by the proportion of proliferating
cells. To address the latter parameter, keratinocyte pro-terminal differentiation, increased proliferation of kera-
tinocytes, inflammatory cell infiltration, and intense angi- liferation was analyzed by bromodeoxyuridine (BrdU)
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incorporation, revealing marked reductions in HPV16/
MMP-9 2/2 mice, at all time points and histologic
stages, compared to HPV16/MMP-9 1/2 controls (Fig-
ure 3). Whereas progression to characteristic dysplasia
and angiogenesis were merely delayed z3–5 months
by the absence of MMP-9 in HPV16 mice, keratinocytes
never fully attained characteristic stage-specific in-
creases in proliferation, even when histologically similar
tissues were compared (albeit at different ages), e.g.,
hyperplasia versus hyperplasia, dysplasia versus dys-
plasia, or in similarly graded tumors. Thus, despite the
propensity toward a higher malignant grade, keratino-
cyte proliferation in MMP-9-deficient SCCs remained
suppressed compared to controls (Figure 3).
The initial induction and increasingly intense angio-
genesis that characterizes the premalignant stages in
the presence of MMP-9 in this pathway (Smith-McCune,
1997; Coussens et al., 1999) is also affected: angiogen-
esis is attenuated much as is keratinocyte proliferation
in the hyperplasias and dysplasias in the absence of
MMP-9. However, while keratinocyte proliferation never
reaches wild-type plateaus, angiogenesis eventually
does, but with a delay of many months (data not shown).
Reactive Stromal Cells Supply MMP-9
during Neoplastic Progression
Increased proliferation and upregulation of MMP-9 in
keratinocytes at the edges of squamous epithelial
wounds have been suggested to provide a migratory
advantage for those keratinocytes (Madlener et al.,
1998). Perhaps the diminished proliferative capacity of
keratinocytes in MMP-9-deficient/HPV16 mice is specif-
ically due to a lack of MMP-9 in HPV16-positive keratino-
cytes. Accordingly, we sought to determine the cellular
sources of MMP-9 in HPV16 transgenic skin (Figure 4).
MMP-9 mRNA was not present in the epithelial or
dermal compartments of normal nontransgenic skin as
determined by in situ hybridization analysis on paraffin-
embedded tissue biopsies (Figure 4A). In characteristic
Figure 2. HPV16/MMP-9 2/2 Mice Develop Fewer, but More Malig- hyperplastic skin, MMP-9 mRNA was not detected, ex-
nant, SCCs
cept in isolated basal keratinocytes abutting skin abra-
(A) Percentage of SCC-free transgenic mice in three cohorts: HPV16/
sions and in some hair follicles (data not shown). InMMP-9 1/1, n 5 133 (FVB/n N14-N20; yellow triangles), HPV16/
contrast, MMP-9 mRNA expression in dysplastic skinMMP-9 1/2, n 5 76 (FVB/n N4; pink squares), and HPV16/MMP-9
was broadly observed in reactive cells residing in the2/2, n 5 137 (FVB/n N4; blue diamonds). Both HPV16/MMP-9 1/1
and HPV16/MMP-9 1/2 mice exhibit an overall SCC incidence of dermis (Figure 4B). In tumors, mRNA expression was
z50% (50% and 47% respectively). In contrast, the incidence of primarily detected in cells localized around capillaries
SCCs in HPV16/MMP-9 2/2 mice was reduced, to z25% (Fisher’s and in a subset of tumor-associated fibroblasts (Figure
Exact Test, p 5 0.0004).
4C). Thus, MMP-9 mRNA showed a dual localization in(B) Immunostaining of intermediate filaments (brown staining) re-
neoplastic skin: It was predominantly restricted to cellsveals degree of keratinocyte differentiation retained in various
in the stroma, rather than the evolving cancer cells;grades of SCC. Well-differentiated Grade I SCCs exhibit hallmark
keratin pearl structures (asterisks) and express the suprabasal kera- sporadic basal keratinocytes in hair follicles also ex-
tin K10 while not expressing the simple keratin K8. Grade II SCCs pressed MMP-9.
appear less differentiated and express both K10 and K8. In contrast, Since reactive inflammatory cells can deliver proMMP-9
poorly differentiated Grade III SCCs lose terminal differentiation
to lesional tissue in preformed granules, we also as-capacity, do not express K10, while maintaining expression of K8.
sessed the presence of pro- and active MMP-9 by immu-Grade IV SCCs attain a spindle cell morphology, exhibit limited K10
nolocalization with MMP-9-specific antibodies in HPV16expression and primarily express the mesenchymal intermediate
filament protein, vimentin. Bar: 50 mm. neoplastic tissue (Figure 4). MMP-9 protein was not de-
(C) A shift in tumor grade in MMP-9 2/2 mice. SCCs were collected
from the three cohorts of mice shown in panel (A) (HPV16/MMP-9
1/1, 133 mice, 67 mice with invasive SCCs, 80 SCCs total; HPV16/
trum of SCC grades, with no incidence of Grade IV SCCs. In contrast,MMP-9 1/2, 76 mice, 35 mice with invasive SCCs, 43 SCCs total;
HPV16/MMP-9 2/2, 137 mice, 37 mice with invasive SCCs, 42 SCCs MMP-9-deficient (2/2) transgenic mice exhibited an altered spec-
trum of SCCs biased toward less differentiated, more malignanttotal) and graded based on the criteria in panel (B). Both MMP-9-
sufficient/HPV16 (1/1 and 1/2) cohorts exhibited a similar spec- cancers (p , 0.0001, Wilcoxon Score for Variable Grade).
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Figure 3. Reduced Epithelial Hyperprolifera-
tion at All Stages of Carcinogenesis in HPV16/
MMP-9 2/2 Mice
Percentage of bromodeoxyuridine (BrdU)-
positive keratinocytes in age-matched nor-
mal FVB/n negative littermates (-LM; [1],
MMP-9 2/2 [1]), and HPV16/MMP-9 1/2 and
HPV16/MMP-9 2/2 mice at 1 and 2 months
[2], 3 and 4 months [3], greater than 5 months
of age [4], and from Grade II SCCs [5]. BrdU-
positive keratinocytes were counted from a
minimum of five high power (403) fields from
five mice per age group. Results are shown
as mean percentages, 6 standard error of
the mean. P values (unpaired, nonparametric
Mann-Whitney) for the respective groups are
0.66 [1], 0.11 [2], 0.73 [3], 0.03 [4], and 0.06
[5], respectively.
tected in normal nontransgenic skin (Figure 4D). In hy- old mice), MMP-9 levels (both pro- and active forms)
were typical for dysplastic lysates from HPV16 controlperplastic skin, MMP-9 was only observed in isolated
mice (compare Figure 5C with Figure 1).capillary-associated cells in the stromal compartment
After transplantation with MMP-9 1/1 BM-d cells(data not shown). In contrast, MMP-9 in dysplastic skin
(Figure 5B), HPV16/MMP-9 2/2 animals were restoredand in carcinomas was detected in many cells in the
to the characteristic phenotypes of neoplastic progres-stromal compartment (Figures 4E and 4F). At higher
sion (from hyperplasia to dysplasia by 4 months of age),magnification, the nuclear and cytoplasmic granule mor-
analogous to the control HPV16/MMP-9 1/2 cohortphology indicated that mast cells (Figure 4G) and neutro-
transplanted with MMP-9 1/1 BM-d cells (data notphils (Figure 4H) were the predominant sources of
shown). Enhanced keratinocyte hyperproliferation in tu-MMP-9 in premalignant tissue. In tumors, MMP-9 was
mors, as assessed by the cell cycle regulated proliferat-also found in neutrophils associated with capillaries
ing cell nuclear antigen (PCNA), was restored in the(Figure 4F), in isolated macrophages (Figure 4I), and the
chimeric HPV16/MMP-9 2/2 mice transplanted withECM in the core of the tumors (Figure 4F). Consistent
MMP-9 1/1 BM-d cells (Figure 6A). By contrast, thewith our previous observations (Coussens et al., 1999),
keratinocyte proliferation index remained low in HPV16/we did not detect mast cells expressing MMP-9 in the
MMP-9 2/2 mice transplanted with MMP-9 2/2 BM-dcore of solid tumors, although MMP-9-positive mast
cells (Figure 6A).cells were associated with invasive tumor fronds at the
Significantly, the tumors in HPV16/MMP-9 2/2 miceperiphery. Thus, MMP-9 was not detected in the onco-
showed a distinct difference in their pattern of proliferat-gene-positive neoplastic cells; rather, it was present
ing keratinocytes, in addition to a reduced proliferationin the ECM and in reactive inflammatory cells populating
index. Whereas proliferating keratinocytes (as revealedthe stroma in the premalignant and malignant stages of
by the S-phase markers BrdU and PCNA) in tumors ofthe SCC pathway.
HPV16/MMP-9 1/1 and 1/2 mice were found through-
out malignant clusters (Figure 6B, panel a), proliferating
Inflammatory Cells Expressing MMP-9 Can Restore keratinocytes in tumors from HPV16/MMP-9 2/2 mice
Characteristic HPV16 Phenotypes were restricted to layers of epithelia in close apposition
The data document the functional involvement of to stroma (Figure 6B, panel b). The diffuse pattern of
MMP-9 in epithelial hyperproliferation, angiogenesis, keratinocyte proliferation was restored in HPV16/
and malignant potential, and reveal the predominant MMP-9 2/2 mice by transplantation of 1/1 BM-d cells
cells expressing it to be inflammatory cells in the stroma (Figure 6B, panel c), but not by transplantation of MMP-9
of dysplasias and tumors. Macrophages, neutrophils, 2/2 BM-d cells (Figure 6B, panel d). These data provide
and mast cells all arise from hematopoietic stem cells evidence that neoplastic cell hyperproliferation is not
in the bone marrow (Weissman, 2000). If inflammatory controlled solely by factors intrinsic to neoplastic cells
cells are a key supplier of MMP-9, then reconstitution such as E6/E7 oncogene expression, but is also regu-
of MMP-9-deficient/HPV16 bone marrow with MMP-9 lated extrinsically by factors emanating from the stroma,
1/1 bone marrow-derived (BM-d) cells should restore under the control of MMP-9.
characteristic neoplastic phenotypes, as seen pre- Furthermore, the chimeric MMP-9/HPV16 mice, where
viously for endochondral ossification in MMP-9 2/2 the sole source of MMP-9 was from BM-d cells, showed
mice (Vu et al., 1998). Accordingly, we lethally irradiated an identical incidence of SCCs (50%) to wild-type (Figure
(7.5 Gy) 1-month-old HPV16/MMP-9 2/2 mice and re- 6C). In contrast, HPV16/MMP-9 2/2 mice transplanted
constituted their bone marrow with either wild-type with MMP-9 2/2 BM-d cells showed delayed neoplastic
(MMP-9 1/1) or MMP-9 2/2 cells (Figures 5A and 5B). progression (data not shown) and less frequent cancers
Wild-type bone marrow (Figure 5B) was successfully (Figure 6C). Intriguingly, HPV16/MMP-9 1/2 mice le-
engrafted into HPV16/MMP-9 2/2 mice. MMP-9 was thally irradiated and transplanted with 1/1 BM-d cells
detected by zymography by eight weeks posttrans- exhibited an increased incidence of SCCs (70%). The
plantation (3-month-old mice; compare Figure 5C with increased incidence was not a simple consequence of
lethal whole-body irradiation since HPV16/MMP-9 2/2Figure 1). By 16 weeks posttransplantation (5-month-
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Figure 4. MMP-9 in Neoplastic Tissue Is Present in Reactive Stromal Cells
(A–C) In situ hybridization analysis of neoplastic tissue from normal and HPV16 transgenic skin for expression of MMP-9 mRNA. Dark-field
photographs of ear-tissue sections from normal nontransgenic ear skin (A), HPV16 dysplastic ear skin (B), and a Grade II SCC (C). The
epidermal (e), dermal (d), cartilagenous (c), malignant tumor keratinocytes (t), and tumor stroma (s) regions of the tissues are indicated. The
epithelial basement membrane is marked with a dashed line. Bar: 50 mm (A); 100 mm (B and C).
(D–I) Immunolocalization of MMP-9 (brown staining) in normal and HPV16 transgenic skin sections counterstained with methyl green from
normal nontransgenic ear (D), dysplastic ear skin (E), and a Grade II SCC (F). High power microscopy reveals presence of MMP-9 in mast cell
granules in dysplasias (G, arrows), consistent with our previous observations (Coussens et al., 1999). In addition, MMP-9 is found in neutrophils
with characteristic bilobed nuclei in both dysplasias and carcinomas (H, arrows). In tumors, MMP-9 is also found in macrophages (I, arrow)
with characteristic membranous folds and finger-like projections, as well as in the ECM (F, arrowheads). The epidermal (e), dermal (d),
cartilagenous (c), malignant tumor keratinocytes (t), tumor stroma (s), and capillaries (*) are indicated. The epithelial basement membrane is
marked with a dashed line. Bar: 50 mm (D); 75 mm (E); 20 mm (F); 10 mm (G); 7 mm (H, I).
mice lethally irradiated and transplanted with MMP-9 MMP-9 increases the rate and broadens the distribution
of hyperproliferation of oncogene-expressing keratino-2/2 BM-d cells retained the z20% incidence of tumors
observed in their nonirradiated, nontransplanted coun- cytes, enhances malignant conversion of dysplasias into
frank carcinomas, and affects differentiation character-terparts. This effect deserves future investigation.
istics of emergent tumors. Furthermore, MMP-9 imparts
these regulatory capabilities on oncogene-positive neo-Discussion
plastic cells as a paracrine factor, originating from reac-
tive inflammatory cells conscripted to support neoplas-This work has uncovered regulatory capabilities for
MMP-9 during squamous carcinogenesis. We found that tic growth and progression.
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Figure 5. Restoration of MMP-9 Activity in MMP-9-Deficient/HPV16 Mice by Bone Marrow Transplantation
(A) Scheme of bone marrow transplantation (BMT) protocol where 1-month-old mice (HPV16/MMP-9 1/2, HPV16/MMP-9 2/2) were lethally
irradiated (7.5 Gy) and transplanted with BM-d cells (1 3106) from nontransgenic donor mice (MMP-9 1/1 or MMP-9 2/2). Each cohort
contained a minimum of ten animals. Ear biopsies were taken at 8 and 16 weeks post-BMT when animals were 3 and 5 months of age. All
animals were studied either until tumors appeared, or animals developed health-compromising phenotypes, or until 12 months of age.
(B) Gelatin-substrate zymography of BM-d cells (1 3 106) from MMP-9 1/1 (1/1, lane 1) and MMP-9 2/2 (2/2, lane 2) donor mice. An arrow
indicates enzymatic activity corresponding to proMMP-9.
(C) Gelatin-substrate zymography of tissue biopsies from HPV16/MMP-9 2/2 mice reconstituted with either wild-type (1/1) or MMP-9-
deficient (2/2) BM-d cells (1 3 106) at 8 and 16 weeks post-BMT. Presence of enzymatic activity corresponding to pro- and active MMP-9,
pro- and active MMP-2, as well as an uncharacterized gelatinase are indicated. Molecular weight markers (kDa) are shown at right.
Paracrine Cell Growth Regulation by MMP-9 How can these effects be rationalized? Based on cur-
rent knowledge, we can envisage several plausible sce-MMPs, including MMP-2 and MMP-9, are expressed in
a wide variety of human and animal cancers, and their narios. The pattern and percentage of proliferating kera-
tinocytes in MMP-9-deficient/HPV16 mice suggests thatroles have historically been associated with invasive and
metastatic phenotypes, particularly in bioassays using MMP-9 could be mobilizing a poorly diffusible growth
factor. In the absence of MMP-9, epithelial cell prolifera-cultured tumor cells (Nelson et al., 2000). In contradis-
tinction, the use of transgenic mice lacking MMP-9 has tion is restricted to one or two layers of cells most proxi-
mal to the stroma, both in dysplasias and in fronds ofclearly demonstrated a much different role for this MMP
in a de novo squamous carcinogenesis model induced cancer cells, whereas with functional MMP-9, proliferat-
ing cells are distributed throughout both lesions. Per-by the HPV16 oncogenes. HPV16 mice lacking MMP-9
have restricted keratinocyte hyperproliferation and de- haps growth factors tethered to the cell surface or stored
in the matrix are released by MMP-9, enabling them tolayed neoplastic progression, from hyperplasia to dys-
plasia to invasive cancer. The biphasic induction and diffuse more widely, producing the observed pattern of
uniform cell proliferation. Indeed, there is precedenceamplification of angiogenesis in the dermis underlying
hyperplasias and dysplasias is delayed. The overall inci- for growth factor storage and release by proteinases
(Werb, 1997; Bergers and Coussens, 2000; Yu and Sta-dence of cancers was reduced from 50% in HPV16 mice
to 27%. Remarkably, the less frequent cancers, con- menkovic, 2000). We anticipate that MMP-9 also regu-
lates angiogenesis by altering the local balance of bio-taining fewer proliferating keratinocytes, were more ma-
lignant, as assessed by classical squamous cancer available angiogenic growth factors. In another mouse
model, of islet carcinoma of the pancreas (Hanahan,grading criteria based on epithelial differentiation mark-
ers. Thus, during tumor progression, MMP-9 serves as 1985), we have recently demonstrated that MMP-9 again
helps regulate angiogenesis, and that it does so in parta paracrine regulator, stimulating proliferation and ma-
lignant conversion of oncogene-positive keratinocytes, by rendering VEGF, an angiogenic inducer molecule,
more available to its receptors on endothelial cells (Ber-enhancing angiogenesis, and yet restricting tumor pro-
gression to more aggressive, poorly differentiated stages. gers et al., 2000). Notably, VEGF is also expressed in
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Figure 6. MMP-9 from Bone Marrow-Derived
Cells Is Sufficient to Restore Wild-Type Neo-
plastic Phenotype in HPV16/MMP-9 2/2
Mice
(A) Percentage of PCNA-positive keratino-
cytes present in Grade I and/or Grade II SCCs
from nonirradiated, nontransplanted, HPV16/
MMP-9 1/1 and 2/2 mice, and from HPV16/
MMP-9 1/2 and 2/2 mice that were lethally
irradiated and transplanted with either wild-
type (1/1) or MMP-9-deficient (2/2) BM-d
cells. PCNA-positive keratinocytes were
counted from a minimum of five high power
(403) fields/tumor analyzed. Results shown
are derived from 5 SCCs each from nonirradi-
ated, nontransplanted HPV16/MMP-9 1/2
[46.6% 6 1.9] and 2/2 [32.3% 6 2.3] mice,
5 SCCs from irradiated/transplanted HPV16/
MMP-9 1/2, BMT 1/1 [45.6% 6 5.0] and
HPV16/MMP-9 2/2, BMT 2/2 [45.9% 6 4.6]
mice, and from the 1 SCC-bearing HPV16/
MMP-9 2/2, BMT 2/2 [29.9% 6 5.1] mouse
(p , 0.05, ANOVA [one-way analysis of vari-
ance]). Results are shown as mean percent-
ages, 6 standard error of the mean.
(B) Keratinocyte proliferation, as measured
by immunoreactivity for proliferating cell nu-
clear antigen (PCNA), in Grade II SCCs from
four cohorts of mice: (a) HPV16/MMP-9 1/2
(b) HPV16/MMP-9 2/2, (c) HPV16/MMP-9
2/2, irradiated and transplanted with MMP-9
1/1 BM-d cells, and (d) HPV16/MMP-9 2/2,
irradiated and transplanted with MMP-9 2/2
BM-d cells. Note in (a) that proliferation is
heterogeneous throughout the malignant
clusters, whereas in (b), proliferation is re-
stricted to within 3–4 cell layers proximal to
stroma (s). Transplantation of MMP-9 1/1
BM-d cells restores the characteristic pattern
of proliferation to keratinocytes (c). Bar: 100
mm (a–d).
(C) Incidence of SCCs in animals from BMT
study (HPV16/MMP-9 1/2, BMT 1/1, n 5 10
mice, 7 with SCCs; HPV16/MMP-9 2/2, BMT
1/1, n 5 10 mice, 5 with SCCs; HPV16/
MMP-9 2/2, BMT 2/2, n 5 11 mice, 1 with
an SCC) was determined in comparison to
nonirradiated, nontransplanted transgenic
animals (HPV16/MMP-9 1/1, n 5 133, 67
mice with SCCs; HPV16/MMP-9 2/2, n 5 137
mice, 37 with SCC).
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the HPV16 model (Smith-McCune et al., 1997). In both tional genetic ablation of individual cell types should
enable their contributions to be assessed.models, the absence of MMP-9 delays angiogenesis and
reduces the frequency of tumors; since angiogenesis is It is clear from our data that a major role for these
inflammatory cells is to deliver MMP-9 to lesional tissue.eventually activated and tumors do form, cryptic com-
pensatory mechanisms are implicated. This is clearly not This single gene product then orchestrates multiple pa-
rameters necessary for full manifestation of the malignantthe case for proliferation of the neoplastic keratinocytes
since neither their proliferation index nor their pattern phenotype initiated by HPV16 oncogenes. Although these
inflammatory cells may not be “transformed” by onco-is restored with ensuing progression.
An alternative explanation to lack of growth factor genes or lose tumor suppressor genes, they clearly
serve the developing neoplasm by amplifying both angi-mobilization for the reduced proliferation and altered
differentiation seen in the absence of MMP-9 could lie ogenesis and neoplastic cell proliferation, and by affect-
ing progression to malignant cancer (this work, andin the nature of the target cell. Perhaps the oncogene-
positive keratinocytes undergoing neoplastic pro- Coussens et al., 1999). It is important to appreciate,
however, that BM-d cells are not the only paracrinegression and malignant conversion in a MMP-9 null envi-
ronment arise from a more primitive squamous stem/ players in the tumor microenvironment. Tumor fibro-
blasts can also contribute to cancer phenotypes (Bou-progenitor cell, which might have different responses
to the HPV16 oncogenes and distinct requirements for dreau and Bissell, 1998; Masson et al., 1998; Olumi et
al., 1999), and endothelial cells are widely investigatedstromal support, with consequentially altered prolifera-
tion and differentiation profiles. Stem cells are believed as viable anti-cancer targets. The signals eliciting the
inflammatory response in the neoplastic lesions remainto proliferate more slowly than their progeny and to
retain embryonic, undifferentiated features (Weissman, to be elucidated.
The important contribution of inflammatory cells ex-2000). Markers delineating epidermal stem/progenitor
cells versus committed basal keratinocytes are still pressing MMP-9 revealed by this study raises the ques-
tion of whether the cells or the factor represents a moreincompletely characterized (Jensen et al., 1999) but
should allow this possibility to be addressed in the tractable target for anti-cancer therapy. If our results,
that MMP-9 enhances angiogenesis and tumor growthfuture.
and is supplied by inflammatory cells, can be general-
ized to human cancer, we envisage that inflammatoryInflammatory Cells as Coconspirators
cell types may come to be another important class ofin Carcinogenesis
tumor-associated cells targeted by anti-cancer drugs.A remarkable result of this study has come in the demon-
While MMP-9 is certainly a key gene product of thesestration that bone marrow-derived inflammatory cells
BM-d cells, it is likely not the only one. A caveat, ofare a sufficient source of MMP-9 to manifest the contri-
course, is the possibility that pharmacological suppres-butions of this proteinase to the HPV16 squamous carci-
sion of inflammatory cells supplying MMP-9 functionnogenesis pathway. It would not have been unreason-
may also select for progression to more poorly differenti-able to predict that MMP-9 is expressed by the
ated cancers. That notwithstanding, it seems plausibledeveloping cancer cells so as to control their own des-
that the efficacy of anti-inflammatory agents such astiny, in the form of induction of angiogenesis and
COX-2 inhibitors (Fosslien, 2000) being ascribed to an-achievement of a diffuse hyperproliferative capability.
giogenesis inhibition and cancer chemoprevention isBut the data reveal otherwise. Although keratinocytes
due to impairment of recruitment and/or function of in-in cell culture can demonstrably express MMP-9 (re-
flammatory cells that supply MMP-9.viewed in Coussens and Werb, 1996; Chambers and
Thus a new perspective has emerged, that tumors areMatrisian, 1997), we found that MMP-9 was not made
complex multicellular enterprises, wherein ostensiblyby keratinocytes in vivo; rather, cells in the stroma of
normal cells are conscripted by transformed cancerhyperplasias, dysplasias, and cancers expressed
cells to make significant contributions to the tumor phe-MMP-9 mRNA and protein. Transfer of MMP-9 1/1
notype (Boudreau and Bissell, 1998; Hanahan and Wein-BM-d cells into MMP-9-deficient/HPV16 mice restored
all phenotypes ascribed to this proteinase in squamous berg, 2000). In particular, this study has demonstrated
carcinogenesis: diffuse keratinocyte proliferation at all that inflammatory cells, especially those expressing
stages, abundant angiogenesis, and progression of in- MMP-9, can be accomplices to neoplastic cells during
vasive cancer in 50% of animals by 1 year; moreover, the squamous carcinogenesis.
predominance of low grade cancer was also restored.
Thus, inflammatory cells are the critical suppliers of
Experimental ProceduresMMP-9 to this carcinogenesis pathway. But which bone
marrow–derived cell type? In the present study, we ob- K14-HPV16 Transgenic and MMP-9 Null Mice
served that neutrophils were abundant in dysplasias and and Tissue Preparation
carcinomas. Mast cells were prevalent in hyperplasias, The K14-HPV16 transgenic mice (Arbeit et al., 1994), the character-
ization of neoplastic stages based on keratin intermediate filamentdysplasias, and at the fronts of invasive cancer, while
expression, and preparation of tissue sections for histologic exami-macrophages were detected in tumors; all three cell
nation have been previously reported (Coussens et al., 1996). Gener-types express MMP-9. T-lymphocytes, which also ex-
ation of MMP-9 homozygous null animals has been reported (Vu etpress MMP-9 (Weeks et al., 1993), were also present in
al., 1998). MMP-9 1/2 mice were bred four generations into FVB/n
neoplastic lesions in these mice (D. Daniels, L. M. C., before intercrossing with HPV16 transgenic mice (N21 FVB/n), in
and D. H., unpublished data). Each of these BM-d cells turn producing MMP-9-deficient (2/2; n 5 133) and MMP-9-profi-
cient (1/2; n 5 76) HPV16 mice.potentially contributes to the supply of MMP-9; condi-
Gelatinase B/MMP-9 Mediates Squamous Carcinogenesis
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Substrate Zymography dissected syngeneic femurs and tibias with PBS. Flushed cells were
dispersed by pipetting, washed, and resuspended in PBS. Nucle-Tissue samples representing distinct histological stages of neoplas-
tic progression, as verified by histological analysis of paraffin- ated cells (1 3 106) in 50 ml were transplanted retro-orbitally into
lethally irradiated animals, 10–12 animals per cohort. Neomycin atembedded sections from adjacent skin, were weighed and then
homogenized (1:4 weight to volume) in lysis buffer containing 50 2 mg/ml was added to the water of the irradiated mice. To verify
engraftment, small (z1 mm2) punch biopsies were removed frommM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.5% deoxycholate,
0.1% SDS. Soluble and insoluble extracts were separated by centrif- ear skin at 3 and 5 months of age and cut in half. One half of each
punch biopsy was subjected to gelatin zymographic analysis tougation and subsequently stored at 2208C. Equivalent amounts of
soluble extract were analyzed by gelatin zymography (Herron et test for MMP-9 activity. The other half of each punch biopsy was
embedded in paraffin (see above) and used for histopathology.al., 1986a, b) on 10% SDS-polyacrylamide gels copolymerized with
substrate (1 mg/ml of gelatin) in sample buffer (10% SDS, 0.25 M
Tris-HCl, 0.1% Bromphenol Blue, pH 6.8). After electrophoresis, gels Acknowledgments
were washed twice for 15 min in 2.5% Triton X-100, incubated for
16 hr at 378C in 50 mM Tris-HCl, 10 mM CaCl2 (pH 7.6), and then We wish to thank Ole Behrendtsen, Alexis Scherl, C. Alex Hartman,
stained in 0.5% Coomassie Blue and destained in 50% methanol. Lidiya Korets, and Helen Capili for technical assistance; Dylan Dan-
Negative staining indicates the location of active protease bands. iels and Nicole Meyer-Morse for assistance with bone marrow trans-
Exposure of proenzymes within tissue extracts to SDS during gel plantation; Alex McMillan for statistical advice; and Gabriele Bergers
separation procedure leads to activation without proteolytic cleav- and Yves DeClerck for critical discussions and insightful comments
age (Talhouk et al., 1991). For inhibition of MMP proteolytic activities, on the manuscript. This work was supported by grants from the
substrate gels were incubated in substrate buffer with 4 mM 1,10- National Cancer Institute (CA72006 to Z. W. and CA 47632 and R37-
phenanthroline (Sigma), as described (Adler et al., 1990). Data shown CA37395 to D. H.) and the American Cancer Society (IRG-9715001
in Figure 1 are representative of results obtained following examina- to L. C.); L. C. gratefully acknowledges startup support provided by
tion of 107 tissue pieces representing various stages of neoplastic the UCSF Comprehensive Cancer Center.
progression in K14-HPV16 transgenic mice. Data shown in Figure
5C are representative of lysates generated from biopsies removed
Received April 4, 2000; revised August 29, 2000.from individual mice (n 5 10) from each respective cohort.
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